J Cancer 2017; 8(18):3667-3674. doi:10.7150/jca.20750
Pancreatic Cancer in Lynch Syndrome Patients
1. Department of Gastroenterology, Hospital Donostia/Instituto Biodonostia, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco UPV/EHU, San Sebastián 20014, Spain;
2. Faculty of Life Sciences, Universidad Isabel I, Spain.
Bujanda L, Herreros-Villanueva M. Pancreatic Cancer in Lynch Syndrome Patients. J Cancer 2017; 8(18):3667-3674. doi:10.7150/jca.20750. Available from http://www.jcancer.org/v08p3667.htm
Although colorectal cancer (CRC) is the most common cancer type in Lynch syndrome (LS) families, patients have also increased lifetime risk of other types of tumors. The accumulated risk of pancreatic cancer (PC) in LS patients is around 3.7% and developed tumors often present a characteristically medullary appearance with prominent lymphocytic infiltration. LS patients are considered in high risk for PC development as they present 8.6-fold increase compared with the general population.
Here we review PC cases reported in LS patients and current management guidelines. Literature data show that LS is clearly associated with PC and recent publications also demonstrated a connection with pancreatic neoplasic precursor lesions such as intraductal papillary mucinous neoplasms (IPMN) in these patients.
While screening techniques are well established for CRC detection, clear strategies are not yet uniform for PC. Magnetic resonance imaging (MRI) and/or endoscopic ultrasound every 1-2 years in MMR mutation carriers with PC in a first or second-degree relative is recommended.
Better pancreatic cancer detection strategies should be urgently defined due to the importance of early diagnosis in this disease.
Keywords: Colorectal cancer, Hereditary, Lynch syndrome, Pancreatic cancer, Risk.